Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Cross-reactivity00:42

Cross-reactivity

Overview
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"TFEB-HNRNPA2B1": A positive feedback loop facilitating metastasis in hepatocellular carcinoma cells.

Experimental cell research·2025
Same author

Deacetylation of ANXA2 by SIRT2 desensitizes hepatocellular carcinoma cells to donafenib via promoting protective autophagy.

Cell death and differentiation·2025
Same author

F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression.

Nature communications·2025
Same author

Corrigendum to "KIAA1429 facilitates metastasis via m6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells" [Canc. Lett. 584 (2024) 216598].

Cancer letters·2025
Same author

Dexamethasone Inhibits the Growth of B-Lymphoma Cells by Downregulating DOT1L.

Cancer reports (Hoboken, N.J.)·2024
Same author

Inhibition of KIAA1429/HK1 axis enhances the sensitivity of liver cancer cells to sorafenib by regulating the Warburg effect.

Biochemical pharmacology·2024

Related Experiment Video

Updated: Jul 17, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

sBAFF mutants induce neutralizing antibodies against BAFF.

Huiguang Gao1, Aina Bian, Yingru Zheng

  • 1Department of Biochemistry and Molecular Biology, Third Military Medical University, Chongqing 400038, China.

FEBS Letters
|January 30, 2007
PubMed
Summary

This study developed novel recombinant proteins to target B cell activating factor (BAFF). These engineered proteins successfully induced neutralizing antibodies against BAFF, offering a potential new strategy for treating autoimmune diseases.

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

Related Experiment Videos

Last Updated: Jul 17, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
08:38

Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge

Published on: April 9, 2012

Area of Science:

  • Immunology
  • Biotechnology
  • Autoimmune Diseases

Background:

  • B cell activating factor (BAFF) is crucial for B lymphocyte survival and maturation.
  • Overexpression of BAFF is implicated in the pathogenesis of autoimmune disorders.
  • BAFF represents a significant therapeutic target for autoimmune conditions.

Purpose of the Study:

  • To engineer and evaluate recombinant proteins as immune inhibitors of human BAFF.
  • To assess the immunogenicity and efficacy of BAFF mutants conjugated with T-helper cell epitopes.
  • To explore a novel strategy for developing therapeutics against BAFF-associated autoimmune diseases.

Main Methods:

  • Conjugation of foreign immunodominant T-helper cell epitopes to BAFF mutants.
  • Expression of recombinant proteins in Escherichia coli and purification via Ni-NTA chromatography.
  • Immunization of BALB/c and hu-SCID mice with recombinant proteins to assess antibody production and neutralizing activity.

Main Results:

  • Recombinant BAFF mutants conjugated with Th epitopes were successfully expressed and purified.
  • Immunization induced high levels of anti-BAFF antibodies in mice.
  • The generated antibodies demonstrated inhibition of BAFF's lymphocyte proliferation-inducing activity and cross-reactivity with BAFF.

Conclusions:

  • Recombinant BAFF mutants modified with Th epitopes can effectively induce neutralizing antibodies against BAFF in vivo.
  • This approach presents a promising strategy for the treatment of BAFF-associated autoimmune diseases.
  • The study highlights the potential of epitope-conjugated protein engineering in developing targeted immunotherapies.